Cargando…

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

BACKGROUND: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jänne, P A, Smith, I, McWalter, G, Mann, H, Dougherty, B, Walker, J, Orr, M C M, Hodgson, D R, Shaw, A T, Pereira, J R, Jeannin, G, Vansteenkiste, J, Barrios, C H, Franke, F A, Crinò, L, Smith, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506393/ https://www.ncbi.nlm.nih.gov/pubmed/26125448 http://dx.doi.org/10.1038/bjc.2015.215

Ejemplares similares

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status
por: Zhang, Jun, et al.
Publicado: (2017)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran
por: Ayatollahi, Hossein, et al.
Publicado: (2018)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value
por: Ahn, Hong-Min, et al.
Publicado: (2023)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
por: Ali, Moiez, et al.
Publicado: (2017)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
por: Imamura, Yu, et al.
Publicado: (2014)

Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
por: Li, Wenbin, et al.
Publicado: (2015)

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
por: Soria, J -C, et al.
Publicado: (2017)

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Pujol, Jean-Louis, et al.
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

KRAS mutations and endometriosis burden of disease
por: Orr, Natasha L, et al.
Publicado: (2023)

Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis
por: Yoshino, T., et al.
Publicado: (2022)

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
por: Warren, Hannah R., et al.
Publicado: (2022)

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
por: Metro, Giulio, et al.
Publicado: (2015)

Oncogenic KRAS promotes malignant brain tumors in zebrafish
por: Ju, Bensheng, et al.
Publicado: (2015)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
por: Agaimy, Abbas, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Cancer
por: Cowzer, Darren, et al.
Publicado: (2022)

Quo vadis, Kras?
por: Schneider, Günter, et al.
Publicado: (2013)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

Kras(P34R) and Kras(T58I) mutations induce distinct RASopathy phenotypes in mice
por: Wong, Jasmine C., et al.
Publicado: (2020)

KRAS Binders Hidden in Nature
por: Bergner, Andreas, et al.
Publicado: (2019)

KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer
por: Renaud, Stéphane, et al.
Publicado: (2016)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
por: Indini, Alice, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h5sd8pp7nrj7shi0h41guc17l8